Market cap of a company in this sector (Drugs/Pharmaceutical) easily reaches 4x the P/S ratio...so for 22M revs in 2017 the RXMD pps fair market value, not even taking its constant market expansion into account, should be around 26+ cents . http://pages.stern.nyu.edu/~adamodar/New_Home...sdata.html
With its current market cap of just 6M RXMD is 15xfold undervalued compared to hundreds of listed companies in this sector.